MCID: FBR017
MIFTS: 56

Fibrosarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Fibrosarcoma

MalaCards integrated aliases for Fibrosarcoma:

Name: Fibrosarcoma 12 74 52 58 29 54 43 15 17 71
Neoplasms, Fibrous Tissue 43 71
Fibrosarcoma of Soft Tissue 12
Fibrous Tissue Neoplasm 12
Fibrocytic Tumor 12

Characteristics:

Orphanet epidemiological data:

58
fibrosarcoma
Prevalence: <1/1000000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:3355
SNOMED-CT 67 53654007
MESH via Orphanet 44 D005354
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0016057
Orphanet 58 ORPHA2030
UMLS 71 C0016057 C0206643 C1336021

Summaries for Fibrosarcoma

Disease Ontology : 12 A connective tissue cancer that has material basis in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern.

MalaCards based summary : Fibrosarcoma, also known as neoplasms, fibrous tissue, is related to congenital fibrosarcoma and adult fibrosarcoma. An important gene associated with Fibrosarcoma is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Degradation of the extracellular matrix. The drugs Etoposide and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and breast, and related phenotypes are Reduced mammosphere formation and shRNA abundance <= 50%

Wikipedia : 74 Fibrosarcoma (fibroblastic sarcoma) is a malignant mesenchymal tumour derived from fibrous connective... more...

Related Diseases for Fibrosarcoma

Diseases in the Fibrosarcoma family:

Adult Fibrosarcoma Congenital Fibrosarcoma

Diseases related to Fibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 542)
# Related Disease Score Top Affiliating Genes
1 congenital fibrosarcoma 34.8 VIM NTRK3 ETV6
2 adult fibrosarcoma 34.5 NTRK3 ETV6
3 infantile myofibromatosis 33.5 VIM NTRK3 ETV6
4 fasciitis 31.3 VIM TNF ETV6
5 rheumatoid arthritis 31.3 TNF TIMP2 TIMP1 MMP9 MMP2 MALAT1
6 aortic aneurysm 31.2 TIMP2 TIMP1 MMP9 MMP2
7 breast adenocarcinoma 31.2 TNF SERPINE1 PLAU MMP9 MMP2
8 osteogenic sarcoma 31.0 TNF MMP2 MALAT1 JUN
9 cellular congenital mesoblastic nephroma 31.0 NTRK3 ETV6
10 aortic aneurysm, familial abdominal, 1 30.9 TIMP2 TIMP1 PLAU MMP9 MMP2 MMP14
11 pneumothorax 30.8 VIM TIMP2 TIMP1 MMP9 MMP2
12 corneal ulcer 30.7 MMP9 MMP2 FN1
13 aortic aneurysm, familial thoracic 1 30.7 TIMP2 TIMP1 MMP9 MMP2
14 periodontitis 30.6 TNF TIMP1 MMP9 MMP2
15 grade iii astrocytoma 30.6 TIMP2 PLAU MMP9 MMP2
16 retinal detachment 30.6 TNF TIMP1 MMP9 MMP2
17 breast secretory carcinoma 30.6 NTRK3 ETV6
18 varicose veins 30.5 TNF TIMP2 TIMP1 MMP9 MMP2 FN1
19 adenocarcinoma 30.4 TIMP2 NTRK3 MMP9 MMP2 MALAT1
20 disseminated intravascular coagulation 30.4 TNF SERPINE1 FN1
21 gastrointestinal stromal tumor 30.3 VIM NTRK3 MMP9 MMP2
22 nasopharyngeal carcinoma 30.3 TNF MMP9 MMP2 MALAT1 JUN
23 renal cell carcinoma, nonpapillary 30.2 VIM TIMP2 MMP9 MMP2 MALAT1 JUN
24 breast cancer 30.1 VIM TNF TIMP2 TIMP1 SERPINE1 PLAU
25 myeloma, multiple 29.9 TNF MMP9 MMP2 MALAT1 MAFB MAF
26 neuroblastoma 29.8 TNF NTRK3 MMP9 MMP2 MALAT1 JUN
27 lung cancer susceptibility 3 29.8 TIMP2 PLAU NTRK3 MMP9 MMP2 MMP14
28 ovarian cancer 29.6 VIM TNF TIMP2 TIMP1 SERPINE1 PLAU
29 hepatocellular carcinoma 29.5 TNF TIMP2 TIMP1 PLAU MMP9 MMP2
30 liver fibrosarcoma 12.5
31 small bowel fibrosarcoma 12.5
32 heart fibrosarcoma 12.4
33 breast fibrosarcoma 12.4
34 kidney fibrosarcoma 12.4
35 central nervous system fibrosarcoma 12.4
36 fibrosarcoma of bone 12.4
37 conventional fibrosarcoma 12.4
38 pediatric fibrosarcoma 12.2
39 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.8
40 dermatofibrosarcoma protuberans 11.8
41 fibroma 11.6
42 desmoid tumor 11.5
43 inflammatory myofibroblastic tumor 11.5
44 chromosome 17q11.2 deletion syndrome 11.2
45 extracranial arteriovenous malformation 10.8 MMP9 MMP2
46 focal myositis 10.8 MMP9 MMP2
47 light chain deposition disease 10.8 MMP9 MMP2 MMP14
48 odontogenic myxoma 10.8 VIM MMP9 MMP2
49 amaurosis fugax 10.8 SERPINE1 MMP9
50 ischemic colitis 10.8 SERPINE1 MMP9 MMP2

Graphical network of the top 20 diseases related to Fibrosarcoma:



Diseases related to Fibrosarcoma

Symptoms & Phenotypes for Fibrosarcoma

GenomeRNAi Phenotypes related to Fibrosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.5 ETV6 JUN MMP14 MMP2 TIMP1 TIMP2
2 shRNA abundance <= 50% GR00343-S 9.36 ETV6 JUN MAF MAFB MAFF MAFG

MGI Mouse Phenotypes related to Fibrosarcoma:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ETV6 FN1 JUN MAFB MMP14 MMP2
2 growth/size/body region MP:0005378 10.41 ETV6 FN1 JUN MAF MAFA MAFG
3 immune system MP:0005387 10.4 ETV6 FN1 JUN MAF MAFB MAFG
4 homeostasis/metabolism MP:0005376 10.39 ETV6 FN1 JUN MAF MAFA MAFB
5 hematopoietic system MP:0005397 10.37 ETV6 FN1 JUN MAFG MAFK MMP14
6 mortality/aging MP:0010768 10.36 ETV6 FN1 JUN MAF MAFB MAFG
7 behavior/neurological MP:0005386 10.35 JUN MAF MAFB MAFG MAFK MMP14
8 cellular MP:0005384 10.3 ETV6 FN1 JUN MAFB MAFG MAFK
9 nervous system MP:0003631 10.21 FN1 JUN MAF MAFB MAFG MAFK
10 integument MP:0010771 10.13 ETV6 FN1 JUN MAF MMP14 MMP9
11 craniofacial MP:0005382 10.09 FN1 MAF MAFB MMP14 MMP2 PLAU
12 muscle MP:0005369 10.09 FN1 MAFG MAFK MMP14 MMP2 MMP9
13 normal MP:0002873 10.02 ETV6 FN1 JUN MAFA MAFB MAFF
14 neoplasm MP:0002006 10.01 ETV6 FN1 MMP2 MMP9 PLAU SERPINE1
15 reproductive system MP:0005389 9.96 FN1 MAFB MAFK MMP14 MMP9 NTRK3
16 respiratory system MP:0005388 9.9 JUN MAFB MMP14 MMP2 MMP9 NTRK3
17 skeleton MP:0005390 9.61 FN1 JUN MAFB MMP14 MMP2 MMP9
18 vision/eye MP:0005391 9.28 JUN MAF MMP14 MMP2 MMP9 NTRK3

Drugs & Therapeutics for Fibrosarcoma

Drugs for Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3 33419-42-0 36462
2
Ifosfamide Approved Phase 3 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
4
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
5
Lenograstim Approved, Investigational Phase 3 135968-09-1
6
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
7
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
8
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
11
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
12
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
13
Histamine Approved, Investigational Phase 3 51-45-6 774
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Isophosphamide mustard Phase 3 0
16 Antirheumatic Agents Phase 3
17 Etoposide phosphate Phase 3
18 Antimitotic Agents Phase 3
19 Anti-Bacterial Agents Phase 2, Phase 3
20 Alkylating Agents Phase 2, Phase 3
21 Antibiotics, Antitubercular Phase 2, Phase 3
22 Topoisomerase Inhibitors Phase 2, Phase 3
23
Liposomal doxorubicin Phase 2, Phase 3 31703
24 Gastrointestinal Agents Phase 3
25 Neurotransmitter Agents Phase 3
26 Dermatologic Agents Phase 3
27 Antipruritics Phase 3
28 Histamine H1 Antagonists Phase 3
29 Serotonin Agents Phase 3
30 Histamine Antagonists Phase 3
31
Histamine Phosphate Phase 3 51-74-1 65513
32 Serotonin Antagonists Phase 3
33 Anti-Allergic Agents Phase 3
34
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
35
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
36
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
37
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
38
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
39
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
40
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
41
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
42
Bevacizumab Approved, Investigational Phase 2 216974-75-3
43
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
46
Estramustine Approved, Investigational Phase 1, Phase 2 2998-57-4 18140 259331
47
Vinorelbine Approved, Investigational Phase 1, Phase 2 71486-22-1 60780 44424639
48
Idarubicin Approved Phase 1, Phase 2 58957-92-9 42890
49
Cytarabine Approved, Experimental, Investigational Phase 1, Phase 2 147-94-4, 65-46-3 6253
50
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
2 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
4 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
5 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
6 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
7 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
9 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
10 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
11 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
12 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
13 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
14 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor Unknown status NCT02261207 Phase 2 Axitinib
17 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
18 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
19 A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma Unknown status NCT01952769 Phase 1, Phase 2
20 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
21 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
22 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
23 A Phase II Study of Imatinib (NSC-716051) in Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans Completed NCT00084630 Phase 2 imatinib mesylate
24 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
25 Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
26 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
27 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
28 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
29 A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy Completed NCT00064220 Phase 2 soblidotin
30 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
31 Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment Completed NCT00041249 Phase 2 brostallicin
32 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
33 Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF) Completed NCT00085475 Phase 2 imatinib mesylate
34 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
35 A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors. Completed NCT01962103 Phase 1, Phase 2 nab-paclitaxel;nab-paclitaxel
36 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
37 Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
38 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
39 A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
40 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
41 A Phase I/II Study of Paclitaxel, Estramustine Phosphate, and Vinorelbine (PaclEVin) Completed NCT00004105 Phase 1, Phase 2 estramustine phosphate sodium;paclitaxel;vinorelbine ditartrate
42 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
43 MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
44 Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an Oral Vascular Endothelial Growth Factor (VEGF), Rapidly Accelerated Fibrosarcoma (RAF) and FMS-like Tyrosine Kinase 3 (FLT3), in Patients With High-risk MDS and AML Completed NCT00542971 Phase 1, Phase 2 Idarubicin;Sorafenib;Ara-C
45 A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC) Completed NCT00326495 Phase 2 Cetuximab;BAY 43-9006
46 Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients Recruiting NCT03023124 Phase 2 Trabectedin;Adriamycin;Dacarbazine
47 ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING) Recruiting NCT03840772 Phase 2 Eribulin
48 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
49 A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations Recruiting NCT04094610 Phase 1, Phase 2 Oral repotrectinib (TPX-0005)
50 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin

Search NIH Clinical Center for Fibrosarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Dacarbazine

Cochrane evidence based reviews: fibrosarcoma

Genetic Tests for Fibrosarcoma

Genetic tests related to Fibrosarcoma:

# Genetic test Affiliating Genes
1 Fibrosarcoma 29

Anatomical Context for Fibrosarcoma

MalaCards organs/tissues related to Fibrosarcoma:

40
Bone, Lung, Breast, T Cells, Liver, Endothelial, Heart

Publications for Fibrosarcoma

Articles related to Fibrosarcoma:

(show top 50) (show all 9664)
# Title Authors PMID Year
1
Biosynthesis and recovery of selenium nanoparticles and the effects on matrix metalloproteinase-2 expression. 54 61
20408816 2010
2
Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. 54 61
20442303 2010
3
TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. 54 61
20406839 2010
4
The human alpha11 integrin promoter drives fibroblast-restricted expression in vivo and is regulated by TGF-beta1 in a Smad- and Sp1-dependent manner. 54 61
19913614 2010
5
The benzoylurea derivative F13 inhibits cell growth, migration and invasion through inducing expression of ERK1/2-mediated RECK in fibrosarcoma HT-1080 cells. 54 61
20051826 2010
6
The role of MT2-MMP in cancer progression. 54 61
20117087 2010
7
Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. 54 61
19551841 2010
8
Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study. 54 61
19862822 2010
9
Inhibition of the expression on MMP-2, 9 and morphological changes via human fibrosarcoma cell line by 6,6'-bieckol from marine alga Ecklonia cava. 54 61
20132738 2010
10
Identification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progression. 54 61
19961596 2009
11
Regulation of homotypic cell-cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains. 54 61
19846557 2009
12
Insulin but not glucagon gene is silenced in human pancreas-derived mesenchymal stem cells. 54 61
19785038 2009
13
VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. 54 61
19910495 2009
14
bFGF induces changes in hyaluronan synthase and hyaluronidase isoform expression and modulates the migration capacity of fibrosarcoma cells. 54 61
19577615 2009
15
[Mechanism of endothelial Rho/Rho kinase in extravascular migration of fibrosarcoma cell]. 54 61
19968078 2009
16
Stabilization of anaphase midzone microtubules is regulated by Rho during cytokinesis in human fibrosarcoma cells. 54 61
19576212 2009
17
Identification of integrins alpha6 and beta7 as c-Jun- and transformation-relevant genes in highly invasive fibrosarcoma cells. 54 61
19405119 2009
18
PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. 54 61
19342157 2009
19
Paeonol exerts anti-angiogenic and anti-metastatic activities through downmodulation of Akt activation and inactivation of matrix metalloproteinases. 54 61
19571375 2009
20
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. 54 61
19478560 2009
21
Autotaxin promotes the expression of matrix metalloproteinase-3 via activation of the MAPK cascade in human fibrosarcoma HT-1080 cells. 54 61
19212832 2009
22
The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions. 54 61
19375915 2009
23
A novel mode of cell detachment from fibrillar fibronectin matrix under shear. 54 61
19401337 2009
24
LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor. 54 61
19366727 2009
25
Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. 54 61
19234490 2009
26
[Triptolide evaluates DNA methylation level of matrix metalloproteinase 9 gene in human fibrosarcoma HT-1080 cells]. 54 61
19526795 2009
27
Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. 54 61
18495463 2009
28
Chondroitin sulfate A regulates fibrosarcoma cell adhesion, motility and migration through JNK and tyrosine kinase signaling pathways. 54 61
19368127 2009
29
Mapping proteolytic cancer cell-extracellular matrix interfaces. 54 61
18600304 2009
30
Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. 54 61
18802920 2008
31
TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. 54 61
19077262 2008
32
Use of the Rad51 promoter for targeted anti-cancer therapy. 54 61
19106292 2008
33
Transcription factors as therapeutic targets for diabetes. 54 61
18851698 2008
34
Glucose regulation of insulin gene expression in pancreatic beta-cells. 54 61
18778246 2008
35
Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver. 54 61
18681831 2008
36
Mapping local matrix remodeling induced by a migrating tumor cell using three-dimensional multiple-particle tracking. 54 61
18641063 2008
37
Flavonoid glycosides isolated from Salicornia herbacea inhibit matrix metalloproteinase in HT1080 cells. 54 61
18715546 2008
38
Wdnm1-like, a new adipokine with a role in MMP-2 activation. 54 61
18492766 2008
39
Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. 54 61
18421307 2008
40
Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. 54 61
18627313 2008
41
Efrapeptin J, a new down-regulator of the molecular chaperone GRP78 from a marine Tolypocladium sp. 54 61
18667784 2008
42
Global and focused transcriptional profiling of small molecule aminopeptidase N inhibitor reveals its mechanism of angiogenesis inhibition. 54 61
18413233 2008
43
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. 54 61
18451175 2008
44
Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. 54 61
18454665 2008
45
Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. 54 61
18483249 2008
46
Human tissue factor pathway inhibitor-2 induces caspase-mediated apoptosis in a human fibrosarcoma cell line. 54 61
18401718 2008
47
A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. 54 61
18392131 2008
48
Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock. 54 61
18283592 2008
49
Collagen-binding domains of gelatinase A and thrombospondin-derived peptides impede endocytic clearance of active gelatinase A and promote HT1080 fibrosarcoma cell invasion. 54 61
18222489 2008
50
Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines. 54 61
17980161 2008

Variations for Fibrosarcoma

Expression for Fibrosarcoma

Search GEO for disease gene expression data for Fibrosarcoma.

Pathways for Fibrosarcoma

Pathways related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 TIMP1 SERPINE1 PLAU MAFK MAFG MAFF
2
Show member pathways
12.67 TIMP2 TIMP1 SERPINE1 MMP9 MMP2 MMP14
3 12.26 TNF PLAU MMP9 MMP2 FN1
4 12.2 PLAU MMP9 MAF ETV6
5 12.13 TNF MMP9 MMP2 MMP14
6 12.04 TNF MMP9 MMP2 JUN
7
Show member pathways
11.99 TNF MMP9 MMP2 FN1
8 11.97 SERPINE1 MMP9 MMP2 MMP14
9 11.93 TNF MMP9 MMP14 JUN
10 11.88 SERPINE1 PLAU MMP14 JUN FN1
11 11.81 TIMP2 TIMP1 MMP9 MMP2
12 11.8 TNF SERPINE1 MMP2 JUN FN1
13 11.79 VIM TNF TIMP1 MMP9 MMP2 FN1
14 11.72 MMP9 MMP2 JUN
15
Show member pathways
11.7 TNF MAF JUN
16 11.66 MMP9 MMP2 MMP14 JUN
17 11.63 MMP9 MMP2 JUN
18
Show member pathways
11.63 TNF TIMP2 TIMP1 MMP9 MMP2 MMP14
19
Show member pathways
11.62 TNF MMP9 MMP2 JUN
20 11.57 TNF SERPINE1 JUN
21 11.57 TNF TIMP1 PLAU MMP9 MMP2
22 11.54 PLAU MMP2 JUN
23 11.5 TNF MMP2 JUN
24 11.45 PLAU MMP9 JUN
25
Show member pathways
11.45 PLAU MMP9 MMP2 JUN
26 11.4 TNF PLAU MMP9 MMP2 FN1
27 11.27 PLAU MMP9 MMP2 JUN
28 11.14 TIMP2 TIMP1 MMP9
29 11.14 MAFK MAFG MAFF MAFB MAFA MAF
30 11.01 TIMP2 TIMP1 SERPINE1 PLAU MMP9 MMP2
31 10.96 VIM TNF TIMP2 TIMP1 NTRK3 JUN
32 10.77 SERPINE1 PLAU

GO Terms for Fibrosarcoma

Cellular components related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 TNF TIMP2 TIMP1 SERPINE1 PLAU MMP9
2 collagen-containing extracellular matrix GO:0062023 9.65 TIMP2 SERPINE1 MMP9 MMP2 FN1
3 platelet alpha granule lumen GO:0031093 9.5 TIMP1 SERPINE1 FN1
4 nuclear chromatin GO:0000790 9.5 MAFK MAFF MAFB MAFA MAF JUN
5 extracellular matrix GO:0031012 9.1 TIMP2 TIMP1 MMP9 MMP2 MMP14 FN1

Biological processes related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.14 MAFK MAFG MAFF MAFB MAFA MAF
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 TNF SERPINE1 MAFG MAFF MAFB MAFA
3 positive regulation of gene expression GO:0010628 9.91 VIM TNF NTRK3 MAFG MAF FN1
4 positive regulation of cell migration GO:0030335 9.9 PLAU NTRK3 MMP9 MMP14
5 blood coagulation GO:0007596 9.88 PLAU MAFK MAFG MAFF
6 angiogenesis GO:0001525 9.85 SERPINE1 MMP2 MMP14 JUN FN1
7 cytokine-mediated signaling pathway GO:0019221 9.8 VIM TNF TIMP1 MMP9 MMP2 FN1
8 circadian rhythm GO:0007623 9.79 SERPINE1 NTRK3 JUN
9 ephrin receptor signaling pathway GO:0048013 9.78 NTRK3 MMP9 MMP2
10 response to hormone GO:0009725 9.74 TIMP2 TIMP1 MMP14
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 TNF MMP2 JUN
12 response to cytokine GO:0034097 9.72 TIMP2 TIMP1 JUN
13 response to organic substance GO:0010033 9.71 TNF TIMP2 TIMP1 JUN
14 collagen catabolic process GO:0030574 9.69 MMP9 MMP2 MMP14
15 cellular response to reactive oxygen species GO:0034614 9.65 MMP9 MMP2 JUN
16 extracellular matrix organization GO:0030198 9.63 TNF SERPINE1 MMP9 MMP2 MMP14 FN1
17 response to amyloid-beta GO:1904645 9.62 MMP9 MMP2
18 lens fiber cell differentiation GO:0070306 9.61 NTRK3 MAF
19 tissue remodeling GO:0048771 9.59 MMP2 MMP14
20 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.58 TIMP2 TIMP1
21 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.56 TNF MMP9 MMP2 JUN
22 negative regulation of metallopeptidase activity GO:1905049 9.52 TIMP2 TIMP1
23 regulation of epidermal cell differentiation GO:0045604 9.49 MAFG MAFF
24 endodermal cell differentiation GO:0035987 9.26 MMP9 MMP2 MMP14 FN1
25 extracellular matrix disassembly GO:0022617 9.02 TIMP2 TIMP1 MMP9 MMP2 MMP14

Molecular functions related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 VIM TNF TIMP2 TIMP1 SERPINE1 PLAU
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.97 MAFK MAFG MAFF MAFB MAFA MAF
3 DNA-binding transcription factor activity GO:0003700 9.92 MAFK MAFG MAFF MAFB MAFA MAF
4 sequence-specific DNA binding GO:0043565 9.86 MAFK MAFG MAFF MAFB MAFA MAF
5 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.7 MAFG MAFF MAFB MAFA MAF JUN
6 protease binding GO:0002020 9.35 TNF TIMP2 TIMP1 SERPINE1 FN1
7 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.23 MAFK MAFG MAFF MAFB MAFA MAF

Sources for Fibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....